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Identification of new process-related impurity 
in the key intermediate in the synthesis of TCV-116
Development of safe and effective drugs requires complete 
impurity evaluation and, therefore, knowledge about the 
formation and elimination of impurities is necessary. Dur-
ing impurity profiling of a key intermediate during synthe-
sis of candesartan cilexetil (1-(((cyclohexyloxy)carbonyl)
oxy)ethyl 1-((2’-(2H-tetrazol-5-yl)-[1,1’-biphenyl]-4-yl)
methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate, 
TCV-116), a novel compound, which had not been reported 
previously, was observed. Structural elucidation of impu-
rity was achieved by liquid chromatography hyphenated to 
different high resolution mass analyzers. Based on exact 
mass measurements and fragmentation pattern, a chloro alkyl 
carbonate ester analogue of the intermediate was identified. 
Structure of the impurity was confirmed by mass spectro-
metric and NMR analyses of the target substance. Identified 
impurity could represent a hazard if it is transferred to the 
final API stage and its presence should be kept below 
allowed limits. Further investigation could reveal whether 
bis(1-chloroethyl) carbonate is a precursor to impurity 
formation. Therefore, synthesis should be regulated so as 
to minimize impurity production. Analysis of the final 
product indicated that the amount of impurity did not 
exceed 50 mg L–1, which represents the detection limit, 
determined according to the signal/noise ratio.
Keywords: candesartan cilexetil (TCV-116), diastereoisomers, 
synthesis, impurity, HRMS
1-(((Cyclohexyloxy)carbonyl)oxy)ethyl-1-((2’-(2H-tetrazol-5-yl)-[1,1’-biphenyl]-4-yl)-
methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (candesartan cilexetil, TCV-116, A 
in Fig. 1) is used to treat hypertension and other related cardiovascular diseases. It was 
introduced by Takeda Pharmaceuticals (Japan) and belongs to the group of sartans, a new 
generation of non-peptide angiotensin II type 1 (AT1) receptor blockers, which were de-
veloped because of partial absorption of saralazine from the gastrointestinal tract. After 
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4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid, CV-11974, B in Fig. 1) oc-
curs (1, 2).
Impurities in an active pharmaceutical ingredient (API) decrease its safety and quality 
and, according to the International Council for Harmonisation, they are generally classified 
as organic and inorganic compounds and residual solvents. Their detection and evaluation 
of their risk level is a necessity in the development of a safe and effective drug. However, 
complete elimination of both the process-related and degradation impurities is a mission 
impossible to accomplish, no matter how strict the regulatory requirements are (3). A very 
important role in impurity level control is that of activities at intermediate stages. 
Appropriate preventive actions ensure higher quality of upcoming intermediates and of 
the final API. Especially hot topics are the genotoxic alerting compounds, for which 
additional attention is required (4). Liquid chromatography coupled with mass spectrometry 
and analogue techniques are among most popular tools for impurity and drug product 
characterization because of their capability of reliable structural elucidation (5).
Knowledge about impurities contributes to an improved and optimized effective syn-
thetic process of selected API. It is known from the literature that eight degradation impu-
rities of candesartan cilexetil were discovered using LC-MS-TOF and it was proven that 
most of them arose under neutral conditions of hydrolysis and photolytic conditions (6). 
Impurities were isolated and their structures were confirmed by NMR spectroscopy. In 
another report, a process impurity of candesartan cilexetil was described and a selective 
method for its assay was proposed (7). Moreover, during target synthesis an API related 
substance, formed via intermolecular N-alkylation, was observed (7). Also, syntheses of 
very common intermediates for TCV-116 and its desethyl, desethoxy and methyl analogues 
Fig. 1. Structure of prodrug TCV-116 (A), its active moiety CV-11974 (B), key intermediate of the 
synthesis of TCV-116 (C) and process-related impurity (D).
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were published (8). Purity of intermediates turned out to be essential for the subsequent 
steps of drug synthesis and its yield. A potentially genotoxic impurity, cilexetil chloride, 
was also discovered with a selective GC/MS analytical method in the API (9).
During our synthesis of TCV-116, a novel process-related impurity (D, Fig. 1) was 
discovered during developmental studies of a key intermediate (C, Fig. 1). 1-Chloroalkyl 
carbonate ester analogue (D, Fig. 1) of the intermediate (C, Fig. 1) was obtained. Based on 
previous studies, chlorine, as a part of the functional group with aliphatic chain, could be 
a genotoxic alerting compound (10). Through further target mass precursor examination, 
it was found that the impurity appeared after esterification reaction of trityl candesartan 
(7, Scheme 1) with halogenated cyclohexyl carbonate (in most cases 1-chloroethyl cyclo-
hexyl carbonate E, Scheme 1), which had already been identified as hazardous (9). It is 
therefore very important to control each stage of the synthesis and develop a synthesis 




HPLC gradient grade solvents: acetonitrile, methanol, acetone, dichloromethane, iso-
propyl acetate and tetrahydrofuran, and LC/MS grade chemicals: ammonium formate, 
ammonium acetate, formic acid and acetic acid were purchased from Merck (Germany). 
Purified water, prepared using a Milli-Q Plus purification system (Millipore, USA) was 
used throughout the studies. Deuterated chloroform for NMR measurements was delivered 
from Sigma Aldrich (Germany). Starting materials for target synthesis, acetaldehyde and 
1-chloroethyl chloroformate, were purchased from Sigma Aldrich. Reaction solvent 1,2-di-
chloroethane was purchased from Kemika (Croatia). Potassium carbonate and magnesium 
sulphate were purchased from Merck.
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Gas chromatography coupled with mass spectrometry
For GC screening of the product isolated in two-step synthesis, the 7890A GC System, 
Agilent Technologies, coupled with a 5975C Inert XL EI/CI MSD mass spectrometer includ-
ing a Triple-Axis detector was used (Agilent Technologies, USA). Chromatographic separa-
tions were run on a DB-WAX column, 30 m × 0.32 mm, 0.25 µm (Agilent Technologies). 
Helium was used as carrier with a flow rate of 2 mL min–1 and nitrogen as makeup gas at 
a flow rate of 25 mL min–1. Injector temperature was set to 140 °C and detector temperature 
to 250 °C. Temperature programme started at 100 °C with an increasing rate of 10 °C min–1 
to 160 °C (10 min or longer if necessary). Split ratio was set to 10:1. Ions were formed via 
positive chemical ionization mode.
Liquid chromatography coupled with mass spectrometry
For HPLC analysis, a liquid chromatograph 1290 UHPLC (Agilent Technologies) and 
Vanquish UHPLC system (Thermo Scientific, USA), resp., equipped with a binary gradient 
pump, degasser, autosampler, column thermostat and diode array detector were utilized. 
Instruments were controlled via HyStar™ 3.2 (Bruker Daltonics, USA) and XCalibur™ soft-
ware (Thermo Scientific), resp. Chromatographic separations were run on two columns: 
Zorbax XDB C18+ 50 mm × 4.6 mm i.d., 1.8 µm particles (Agilent Technologies) and Accu-
core Vanquish C18 100 mm × 2.1 mm i.d., 1.5 µm particles (Thermo Scientific). Aqueous 
mobile phase, 10 mmol L–1 ammonium acetate (pH = 7.0), and organic mobile phase, aceto-
nitrile, were used in a gradient mode: the initial mobile phase with 5 % acetonitrile lin-
early changed in 20 min to a mobile phase containing 98 % of acetonitrile and remained 
constant for 5 min. Flow rate was set to 0.7 on Zorbax and to 0.1 mL min–1 on Vanquish 
column and analyses were performed at room temperature. Injection volume was 2 µL and 
autosampler temperature was set to 10 °C. Detection was performed at the wavelength of 
230 nm. Samples (approximate concentration 0.3 mg mL–1) were dissolved in tetrahydro-
furan and diluted with acetonitrile to the final volume.
Mass spectrometer was coupled with the liquid chromatograph via a splitter at a 
10:1 ratio. Mass measurements were carried out on a MaXis Impact™ mass spectrometer 
(Bruker Daltonics, USA) and LTQ Orbitrap XL™ (Thermo Scientific), resp. Ionization was 
performed by electrospray using a Maxis instrument (ESI) and heated electrospray ion 
source on an LTQ Orbitrap mass spectrometer (hESI). Time of flight analyzer (MaXis Im-
pact) with a dual ion funnel, quadrupole, high transmission CID cell and flight tube with 
a dual stage reflector was applied. Long life lash detector enabled ultra-fast acquisition 
speed up to 50 Hz and high mass accuracy across the entire mass range. Mass spectrom-
eter was controlled via the otof Control 5.3.14.0 program and data were evaluated with 
Compass Data Analysis 4.1 (Bruker Daltonics GmbH Software, USA). N2 was a sheath and 
auxiliary gas, source voltage was set to 4.5 kV and capillary temperature at 250 °C, dry gas 
was set to 8 mL min–1 and nebulizer to 1.5 bars. Generated ions were detected with a quad-
rupole. Ion transfer was taken in 80–120 µs range and pre-pulse storage time in 8–12 µs 
range. Funnel RF 1 and 2 were set to 250 Vp-p. Mass range m/z from 100 to 2000 with rolling 
(moving) average 2 was included. Fragmentation MS/MS studies were performed at nor-
malized collision energy from 25 to 40.7 eV.
LTQ Orbitrap XL™ hybrid Ion Trap-Orbitrap mass spectrometer, as a matter of fact 
Fourier transform mass spectrometer (FTMS) based on Thermo Scientific™ LTQ XL™ linear 
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ion trap, and Orbitrap mass spectrometer technologies with an HCD collision cell for ad-
vanced research were controlled with XCalibur™ software and with LTQ Tune 3.2.2 (Thermo 
Scientific). Heated electrospray was set to 320 °C and capillary voltage to 45 V. Sheath gas 
was set to 55 and auxiliary gas to 7 mL min–1. Mass range m/z from 100 to 2000 was recorded. 
Fragmentation MS/MS studies were performed at normalized collision energy of 35 eV.
Syntheses of reference materials
Synthesis of bis(1-chloroethyl) carbonate (compound F). – Synthesis was performed on the 
basis of 1-haloalkyl carbonate synthesis described in the literature (11). A catalytic amount 
of pyridine (4.97 mmol, 0.4 mL) was added to a stirred solution of 1-chloroethyl chlorofor-
mate (9.3 mmol, 1.0 mL) and acetaldehyde (14.3 mmol, 0.8 mL) in 1,2-dichloroethane (10.0 
mL). Solution was then heated to 80 °C for 4 h. When the reaction was completed, the 
mixture was cooled down to room temperature and water was added (15 mL). Layers were 
separated and water fractions were extracted with dichloromethane (10 mL). Combined 
organic layers were dried with anhydrous MgSO4 and filtered. Final product was obtained 
by vacuum evaporation. Structure of the main product was determined via GC-MS.
Synthesis of 1-(((1-chloroethoxy)carbonyl)oxy)ethyl 2-ethoxy-1-((2’-(2-trityl-2H-tetrazol-
5-yl)-[1,1’-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate (compound D). – To a solu-
tion of potassium carbonate in dimethylacetamide (110 mg mL–1) in a round bottom flask, 
2-ethoxy-1-((2’-(2-trityl-2H-tetrazol-5-yl)-[1,1’-biphenyl]-4-yl)methyl)-1H-benzo[d]imidaz-
ole-7-carboxylic acid (0.30 mmol, 0.20 g) and bis(1-chloroethyl) carbonate (F, Scheme 1) (0.30 
mmol, 0.05 g) were added and the reaction mixture was heated for 3 h at 60 °C. The reaction 
mixture was then cooled to room temperature and washed with isopropyl acetate (10 mL) 
and then water (10 mL). Combined organic phases were dried with anhydrous MgSO4 and 
filtered. Raw material was obtained by vacuum evaporation. To an oil residue, diethyl 
ether was added and left under stirring overnight. Crude product was obtained by vacu-
um evaporation. At the end, the oiled residue was left to macerate in hexane for about 1 h. 
A suspension was formed and then the product was filtered. Purity and authenticity of the 
product were determined by LC-MS.
Semi-preparative HPLC
Impurity compound D (Fig. 1) was isolated using the 1200 prepHPLC system with a 
binary gradient pump, UV detector, autosampler hyphenated to a MSD G6130A single 
quad mass spectrometer (Agilent Technologies). Instrument was controlled with Chem-
Station Software 4.03 (Agilent Technologies). Preparation column Luna C18, 150 mm × 21.2 
mm i.d., 5 µm particles (Phenomenex, USA), was used at 30 °C. The same gradient mobile 
phase was used as described previously at a flow rate of 44 mL min–1 in 100:1 split ratio to a 
MSD mass spectrometer. Samples (approximate concentration 100 mg mL–1) were prepared 
by dissolving a sample in a small volume of tetrahydrofuran, and then acetonitrile was 
added to the final volume. Injection volume was 100 mL and UV detection was monitored at 
230 nm. Fractions of target impurity were collected at retention times around 23 min and the 
impurity was back extracted with dichloromethane. Organic phases were collected and 
dried with MgSO4. Suspension was filtered and the solvent was removed by vacuum evapo-
ration. Structure of the isolated substance was confirmed by NMR and LC-ESI-MS.
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Fig. 2. HPLC chromatogram after injection of trityl carboxylate solution (C). Two additional peaks, X 
and Y, were observed.
NMR spectroscopy
1D and 2D NMR experiments were performed on a 400 MHz Varian NMR spectrom-
eter (Varian, USA) at 25 °C. All spectra were acquired for samples dissolved in CDCl3. 
1H 
and 13C chemical shifts (d, ppm) were reported relative to TMS as internal standard.
RESULTS AND DISCUSSION
As every stage of API synthesis should be evaluated, HPLC analyses of the key inter-
mediate C in the synthesis of A were performed (Fig. 1). In HPLC chromatograms (Fig. 2), 
after injection of trityl carboxylate solution C (Fig. 1), two unknown peaks (X and Y) be-
tween 11.7 and 11.9 min were observed. Mass spectra showed that both peaks had the same 
m/z value of 833 with additional adduct ions, for example, [M+Na]+ with m/z 855 and [M+K]+ 
with m/z 871 confirming m/z of the molecular ion (Fig. S1). MS2 spectra of both peaks 
showed the same fragmentation and isotope pattern and the presence of chlorine could be 
indicated. According to exact mass measurements, UV spectra and ion fragmentation 
spectra via a qTOF high resolution analyzer, C48H42ClN6O6+ chemical formula for the 
[M+H]+ ion was proposed and can be assigned to chloroalkyl carbonate ester impurity D 
(Fig. 1). This compound has a chiral centre in the structure and therefore a diastereoiso-
meric mixture was expected and two peaks in the LC-MS chromatogram can be explained. 
From the proposed impurity structure and regarding the route of synthesis presented in 
Scheme 1, no detection of impurity before the last step of the synthetic route is expected. 
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Target mass search confirmed this hypothesis as impurity precursor was not found at 
previous steps of the synthesis. Moreover, synthon, as bis(1-chloroethyl) carbonate (F, 
Scheme 1) instead of 1-chloroethyl cyclohexyl carbonate (E, Scheme 1), which was utilized 
in esterification reaction, was estimated to be present and to cause impurity formation.
In addition, traces of bis(1-chloroethyl) carbonate (F, Scheme 1) were detected via GC-
MS (Fig. S2) in 1-chloroethyl cyclohexyl carbonate (E, Scheme 1) and correlation between 
bis(1-chloroethyl) carbonate (F, Scheme 1) and final chloroalkyl carbonate ester impurity 
(D, Fig. 1) was observed (R = 0.99; significance at a = 0.05). According to a noticeable trend, 
we also confirmed that the impurity did not increase during the esterification reaction, but 
was formed due to the bis(1-chloroethyl) carbonate F presence. Reagent F was formed dur-
ing the synthesis (Scheme 1) and apparently under such reaction conditions partial di-
merization of 1-chloroethyl chloroformate to bis(1-chloroethyl) carbonate (F, Scheme 1) 
could occur. 
To investigate in detail the occurrence of impurity D (Fig. 1), a target two-step synthe-
sis was performed. The first step was target synthesis of reagent F according to the synthe-
sis of 1-haloalkyl carbonates described in the literature (11). F is not commercially available 
and represents the main starting compound in the second step where esterification reac-
tion of crude trityl candesartan acid intermediate 7 (Scheme 1) led to formation of chloro-
alkyl ester impurity D (Fig. 1) as the main compound. Synthesis was performed under the 
same conditions as the synthesis of key intermediate C, except for bis(1-chloroethyl) car-
bonate F, which was used instead of 1-chloroethyl cyclohexyl carbonate E. Crude product 
containing about 30 % of chloroalkyl ester D (Fig. 1) was isolated via preparative chroma-
tography (Fig. S3). According to mass spectrometric data (Fig. S5), structures of two peaks 
with similar retention times (Fig. S4) were confirmed in isolated material. In the MS full 
scan spectrum of impurity D (Fig. 1), a large peak at m/z = 243 was observed and some 
other small peaks beside the molecular ion and its adducts (Table I, Fig. S6). Exact mass 
data indicated that the trityl group was not stable during ion formation. Further investiga-
tion showed that settings of the ion source (e.g., temperature) influenced the degradation 
of this substance during MS scan. For example, during hESI+ ionization (temperatures 
higher than 300 °C), fragment [M+H]+ = 805 (HRMS measurements indicate characteristic 
nitrogen cleavage from tetrazole group) appeared with higher intensity than the molecular 
ion [M+H]+ = 833 or its adducts, for example [M+Na]+ (12). Contrary to this, ESI+ ionization 









RDB (rings and 
double bonds)a
833.2819 C48H42ClO6N6+ 833.2849 –3.5 30.5
805.2746 C48H42ClO6N4+ 805.2787 –5.2 29.5
711.3038 C45H39N6O3+ 711.3078 –5.7 29.5
591.1714 C29H28ClO6N6+ 591.1753 –6.7 18.5
243.1158 C19H15+ 243.1168 –4.1 12.5
a RDB=C-H/2+N/2+1
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RDB (rings and 
double bonds)a
441.1662 C24H21N6O3+ 441.1670 +1.7 17.5
423.1545 C24H19N6O2+ 423.1564 –4.4 18.5
395.1485 C24H19N4O2+ 395.1503 –3.9 17.5
380.1378 C24H18N3O2+ 380.1394 –4.0 17.5
367.1175 C22H15N4O2+ 367.1190 +4.0 17.5
352.1064 C22H14N3O2+ 352.1081 +4.8 17.5
349.1073 C22H13N4O+ 349.1084 –3.0 18.5
338.1036 C20H15N5O+ 338.1036 –0.1 17.5
263.1278 C16H15N4+ 263.1278 –0.1 6.5
235.1224 C14H11N2+ 235.1230 –2.4 10.5
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(ordinary temperatures) generates the same fragment of m/z 805 during the ionization 
process with lower intensity and it may be assumed that ion source temperature consider-
ably influences the substance degradation during ionization.
In general, there are no conditions in ion source that could prevent fragmentation of 
the labile trityl group as m/z 243 appears with every modification of ionization parameters. 
Based on this knowledge, fragmentation in ion source is proposed in Scheme 2.
Basic fragment in the MS2 spectrum confirmed the presence of trityl ion, other frag-
ments are less intensive and therefore structure interpretation is complicated. Consequent-
ly, for structure identification, the part of the molecule without trityl group (Fig. S7), 
Scheme 3
Fig. 3. Proposed structures of fragment m/z 395.150 according to theoretical calculations.
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Table III. 1H and 13C NMR chemical shift assignment with atom labelling
Atom label 1H, dH (ppm) 13C, dC (ppm)
2 / 158.75, 158.77
4 / 141.90, 141.94
5 7.77 122.76, 122.81
6 7.17 120.83, 120.87
7 7.56 124.03, 124.06
8 / 114.31, 114.35
9 / 131.96, 132.00
10 / 163.70, 163.75
11 6.85, 6.86 92.39
12 / 150.91, 150.96
13 6.38, 6.40 84.60, 84.69




18 5.52-5.59 46.98, 47.01
19 / 139.99, 140.04
20 6.95-7.03 129.42
21 6.71-6.78 126.14
22 / 135.64, 135.65
23 6.71-6.78 126.14
24 6.95-7.03 129.42
25 / 141.67, 141.76
26 / 126.31
27 7.86 130.31, 130.35
28 7.38-7.49 127.43, 127.47
29 7.38-7.49 129.86, 129.90







M+H+ = 591, was isolated and MS3 experiment was performed. Structure was postulated 
on the basis of 591 ion fragmentation (Table II, Fig. S8). A possible mechanism of frag-
mentation was proposed (Scheme 3) and analogy to candesartan cilexetil (A) fragmenta-
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tion mechanism was found (6). Theoretical calculations showed that protonated sartans 
and the related analogues tend to form N-substituted-3- substituted phenanthridin-
6-amine ion, which has a large conjugated structure; therefore, six-membered ring struc-
tures of fragments after neutral loss of N2 or CO2 (13) can be proposed. In the literature, 
relative Gibbs free energies of precursor and product ions were calculated using the den-
sity functional theory. In accordance with the calculations, six-membered ring structures 
of the fragments appear to be thermodynamically the most stable ones (Fig. 3).
According to the MS2 spectrum of both chromatographic peaks, we could confirm two 
isomers, since no difference was found in the fragmentation spectrum. In contrast to the 
MS spectrum, the intensity of fragments does not vary according to different fragmenta-
tion energy, possibly due to preliminary decomposition during ionization.
To confirm the structure of impurity D, NMR analyses of isolated material were per-
formed. Complete proton and carbon chemical shift assignments with atom labelling are 
given in Table III and Fig. 4. Two sets of signals are observed in the spectra (Fig. S9) and 
consequently the diastereoisomeric mixture of impurity D can be confirmed. Signals at 
1.75 and 1.80 ppm (doublets) match the methyl groups and are coupled to downfield shift-
ed signals at 6.38 and 6.40 ppm (quartets). 13C chemical shifts at 84.60 and 84.69 ppm (Fig. 
S10) are deshielded due to the presence of heteroatoms (oxygen and chlorine). Aromatic 
proton at 7.86 ppm shows correlation with tetrazole carbon at 164.02 ppm, identifying the 
trityl substituent at N-2 position of tetrazole ring (2D HMBC experiment, Fig. S11) (14). 
CONCLUSIONS
Novel process-related impurity1-(((1-chloroethoxy)carbonyl)oxy)ethyl 2-ethoxy-
1-((2’-(2-trityl-2H-tetrazol-5-yl)-[1,1’-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-car-
boxylate (D) with a hazardous potential for being present in final API was discovered by 
liquid chromatography during impurity profiling of a key intermediate C during synthe-
sis of trityl protected active substance TCV-116 (A). Two diastereoisomers of D were identi-
fied on the basis of mass and NMR spectra. In the course of further investigation and 
target synthesis, it was found that bis(1-chloroethyl) carbonate (F) was the precursor for 
impurity formation. In order to assure quality and safety of the key intermediate and 
consequently of the final API, it was very important to keep compound F at low level dur-
ing synthesis. According to these results and implementation of synthetic strategy, where 
the identified impurity did not appear, either at the intermediate stage or in final API, the 
Fig. 4. NMR atom labelling.
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above detection limit of 50 mg L–1 could be achieved. The present study offers an important 
contribution to structural investigation of impurities related to TCV-116 and consequently 
to the synthetic design of selected API.
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